CSF3 and Thrombocytopenia: Previous studies have also highlighted that the events most frequently reported were G3–4 neutropenias: the StiL trial registered 37% incidence of neutropenia, but only 3% of anemia and 5% of thrombocytopenia [8]; even higher neutropenia rates were observed in a similar population in the BRIGHT study (49% grade 3–4), despite 29% of patients receiving G-CSF prophylaxis at any cycle.